Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Name||female reproductive organ cancer|
|Definition||A reproductive organ cancer that is manifested in the female genitals. This includes organs such as the ovaries, fallopian tubes, uterus, cervix, vagina and vulva.|
|Alt Ids||DOID:1244 DOID:1281|
|Path||disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer female reproductive organ cancer|
|Molecular Profile||Therapy||Indication/Tumor Type||Response Type||Profile Response Detail|
|Unknown unknown||Durvalumab + Olaparib||female reproductive organ cancer||not applicable||detail...|
|Unknown unknown||Cediranib + Durvalumab||female reproductive organ cancer||not applicable||detail...|
|Unknown unknown||Pamiparib||female reproductive organ cancer||not applicable||detail...|
|PIK3CA mutant||Capivasertib||female reproductive organ cancer||predicted - sensitive||detail...|
|BRAF D594N||Trametinib||female reproductive organ cancer||no benefit||detail...|
|BRAF N581S||Trametinib||female reproductive organ cancer||no benefit||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT00800345||Phase I||Pazopanib + Topotecan||Phase I Trial of Oral Metronomic Topotecan and Oral Pazopanib to Treat Recurrent/Persistent Gynecologic Tumors||Completed|
|NCT01831089||Phase I||Bevacizumab + Lurbinectedin + Paclitaxel Lurbinectedin + Paclitaxel||Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors||Completed|
|NCT03073525||Phase II||Atezolizumab + FANG vaccine||Trial of Atezolizumab and Vigil for Advanced Gynecological Cancers (A Companion Study to CL-PTL-119)||Active, not recruiting|
|NCT03277482||Phase I||Durvalumab + Tremelimumab Durvalumab||Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer||Recruiting|
|NCT04042116||Phase Ib/II||Lucitanib + Nivolumab||A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor||Recruiting|
|NCT04273061||Phase II||Atezolizumab||Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity (CAPTIV-8)||Recruiting|
|NCT04395079||Phase II||Tremelimumab Durvalumab||Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies||Not yet recruiting|